Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco

Name	Symbol	Market	Type
Capital Group Fixed Income ETF Trust	AMEX:CGCP	AMEX	Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	22.48				0	09:09:54

Capital Group Fixed Inco... (AMEX:CGCP)
Historical Stock Chart

From Jun 2019 to Jun 2024

Click Here for more Capital Group Fixed Inco... Charts.

IRVINE, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a global leader of innovative therapies for ischemic cardiac disease and the market leader of surgical products for transmyocardial revascularization (TMR), sponsored an educational symposium titled "Advancements in Revascularization & Stem Cell Therapy," which was attended by over 40 cardiothoracic surgeons. The Program Chair was Dr. Emerson Perin, Director, New Interventional Cardiovascular Technology, Texas Heart Institute. "The objective of the symposium is to provide cardiac surgeons with a state of the art update on the application of stem cells in cardiovascular medicine, including exciting new information on TMR plus cell therapy. Cardiologists are challenged everyday in treating medically refractory patients suffering from chronic ischemia. This program highlights recent advancements with TMR plus cell therapy for the treatment of chronic ischemia, including innovative new tools available to surgeons today," explained Dr. Perin. He continued, "While there is still much to be learned about the therapeutic potential of stem cells, the safety and feasibility of autologous bone marrow stem cells in cardiac applications is well established. There are obvious advantages to intramyocardial cell delivery in the surgical setting - including precision and control, and the strategy of delivering platelet rich plasma in conjunction with minimally invasive TMR is a logical initial step." The symposium included presentations of real world experiences with TMR as well as TMR plus cell therapy. -- Dr. Guillermo Reyes, a cardiothoracic surgeon from Madrid presented his early experience using the Cardiogenesis PHOENIX delivery system which in this series combined TMR plus autologous bone marrow stem cells. The 12 month outcomes on 16 patients included the elimination or significant reductions in angina, with no mortality and no major adverse events. -- Dr. Kurt Wehberg, a cardiothoracic surgeon from Salisbury, MD described the implementation of a minimally invasive Fast Track TMR program. Using a strict patient care protocol, combined with minimally invasive thoracotomy technique, he reported a time to discharge postoperatively of 23 hours for 80% of his stand alone TMR patients. Dr. Wehberg also presented 6 month follow up on 11 patients treated with TMR plus platelet rich plasma (PRP). The 6 month outcomes included a significant reduction in angina (82% of patients free of angina) and a trend towards improvement in ejection fraction. "This symposium outlines the Company's progress on developing breakthrough clinical tools in treating the increasing problem of ischemic heart disease and refractory angina. Intraoperative TMR both as stand alone therapy and as an adjunct to coronary bypass surgery has proven effective in randomized, controlled clinical trials. We believe that the future of TMR plus cell therapy can make this a more potent technology with significantly greater clinical adoption," said Richard Lanigan, President of Cardiogenesis. "We will build on this successful event by driving the awareness of the benefits of minimally invasive TMR to the referring cardiology community as well as work towards initiating a U.S. clinical trial of TMR plus cell therapy." About Cardiogenesis Corporation Cardiogenesis specializes in providing surgical devices to treat cardiovascular disease and severe angina. The Company's market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a procedure known as Transmyocardial Revascularization (TMR). To date, thousands of patients have been treated with the Cardiogenesis TMR technology. For more information on Cardiogenesis, please visit the Company's website at http://www.cardiogenesis.com/. Cardiogensis also maintains a website where patients suffering from angina can learn more about the TMR procedure at http://www.heartofnewlife.com/. Safe Harbor Statement With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the Company's technologies and the effect of such technologies on the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. DATASOURCE: Cardiogenesis Corporation CONTACT: William R. Abbott, Senior Vice President and Chief Financial Officer of Cardiogenesis Corporation, +1-949-420-1800 Web Site: http://www.cardiogenesis.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CGCP Capital Group Fixed Income ETF Trust